| Drug Name |
Avanafil |
| Drug ID |
BADD_D00192 |
| Description |
Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition.[L32113]
It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113] |
| Indications and Usage |
Treatment of erectile dysfunction in males. |
| Marketing Status |
Prescription |
| ATC Code |
G04BE10 |
| DrugBank ID |
DB06237
|
| KEGG ID |
D03217
|
| MeSH ID |
C553414
|
| PubChem ID |
9869929
|
| TTD Drug ID |
D0Y5JC
|
| NDC Product Code |
72384-751; 53360-1143; 53360-1142; 72384-752; 76299-322; 76299-320; 69037-0019; 72384-753; 76299-321; 53360-1141; 14501-0090 |
| Synonyms |
avanafil | 4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)-1-pyrrolidinyl)-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide | stendra |
